The Efficacy & Safety of the UAS Immunotherapy Protocol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01699659|
Recruitment Status : Completed
First Posted : October 4, 2012
Last Update Posted : October 4, 2012
|Condition or disease||Intervention/treatment|
|Perennial Allergic Rhinitis With Seasonal Variation||Other: allergen immunotherapy|
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||The Efficacy and Safety of the United Allergy Service (UAS) Immunotherapy Protocol|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
Other: allergen immunotherapy
- change in symptom scores from 12 months before therapy initiation in contrast to determination during 1 to 2 years of therapy (retrospective). [ Time Frame: Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy. ]Enrolled patients completed surveys pertinent to symptom scores, contrasting current status on immunotherapy compared (by recall) to a 12 month time point prior to initiation of therapy.
- Changes in medication plus symptom aggregate score. [ Time Frame: Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy. ]Aggregate Medication and Symptom surveys were compared to determine changes from a 12 month time point prior to inception of therapy to current time point of 1 to 2 years of therapy.
- Quality of Life (QOL) scores [ Time Frame: Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy ]QOL scores will be calculated after one to 2 years of therapy and contrasted with QOL reflecting status 12 months prior to initiation of therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01699659
|United States, Texas|
|San Antonio, Texas, United States, 78216|
|Principal Investigator:||Frederick M Schaffer, M.D.||United Allergy Services|